AU560595B2 - Human-human hybridomas for neoplasms - Google Patents

Human-human hybridomas for neoplasms

Info

Publication number
AU560595B2
AU560595B2 AU17729/83A AU1772983A AU560595B2 AU 560595 B2 AU560595 B2 AU 560595B2 AU 17729/83 A AU17729/83 A AU 17729/83A AU 1772983 A AU1772983 A AU 1772983A AU 560595 B2 AU560595 B2 AU 560595B2
Authority
AU
Australia
Prior art keywords
human
monoclonal antibodies
cells
hybridomas
host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU17729/83A
Other languages
English (en)
Other versions
AU1772983A (en
Inventor
Mark C Glassy
Hideaki Hagiwara
Yoshihide Hagiwara
Harold H. Handley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU1772983A publication Critical patent/AU1772983A/en
Application granted granted Critical
Publication of AU560595B2 publication Critical patent/AU560595B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU17729/83A 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms Expired AU560595B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57084843A JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法
JP57-84843 1982-05-21

Publications (2)

Publication Number Publication Date
AU1772983A AU1772983A (en) 1983-12-16
AU560595B2 true AU560595B2 (en) 1987-04-09

Family

ID=13842073

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17729/83A Expired AU560595B2 (en) 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms

Country Status (13)

Country Link
EP (1) EP0109441B1 (enExample)
JP (2) JPS58201994A (enExample)
AT (1) ATE114189T1 (enExample)
AU (1) AU560595B2 (enExample)
CZ (1) CZ280677B6 (enExample)
DE (1) DE3382764T2 (enExample)
DK (1) DK164510C (enExample)
FI (1) FI86077C (enExample)
HU (1) HU190908B (enExample)
IN (1) IN157982B (enExample)
SK (1) SK356683A3 (enExample)
WO (1) WO1983004313A1 (enExample)
ZA (1) ZA833686B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU589351B2 (en) * 1984-01-31 1989-10-12 Litton Bionetics, Inc. Tumor specific monoclonal antibodies

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618577A (en) * 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
EP0118365B1 (en) * 1983-03-04 1990-08-29 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells
US4693966A (en) * 1983-03-11 1987-09-15 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
SE8401945L (sv) * 1983-04-08 1984-11-13 Kureha Chemical Ind Co Ltd Antikropp mot cancer i urinblasan hos menniska
WO1985002411A1 (en) * 1983-11-25 1985-06-06 The University Of Melbourne Cell line and monoclonal antibody
US4886745A (en) * 1984-03-30 1989-12-12 Syntex Inc. Monoclonal antibody specific for human basal cell surface antigen
AU4070685A (en) * 1984-03-30 1985-10-03 Board Of Trustees Of The Leland Stanford Junior University Monoclonal antibody specific for human basal cell surfaces
JPS6133125A (ja) * 1984-07-25 1986-02-17 Morinaga & Co Ltd ヒト単クロ−ン性抗肺ガン細胞抗体
US4761377A (en) * 1984-10-15 1988-08-02 The Regents Of The University Of California Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
EP0183876A1 (en) * 1984-11-27 1986-06-11 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal antibodies for endotoxin core and their use
US5106746A (en) * 1985-05-22 1992-04-21 E. I. Du Pont De Nemours And Company Process for the in vitro immunization of human splenocytes against tumor associated antigens
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
JPH0655680B2 (ja) * 1985-10-26 1994-07-27 萩原 義秀 悪性腫瘍用ヒトモノクロナル抗体複合剤
EP0222360A3 (en) * 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
JPH0767388B2 (ja) * 1986-01-13 1995-07-26 三菱化学株式会社 抗体産生細胞株の樹立方法
AU7165891A (en) * 1989-12-18 1991-07-18 Board Of Regents, The University Of Texas System Tumor-specific, cell surface-binding monoclonal antibodies
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
JPH04346792A (ja) * 1991-05-22 1992-12-02 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列
EP0528663B1 (en) * 1991-08-16 1997-10-29 Kabushiki Kaisha Toshiba Monoclonal antibody to a synaptophysin
KR20010022846A (ko) 1997-08-15 2001-03-26 나가야마 오사무 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제
DE60039893D1 (enExample) 1999-08-23 2008-09-25 Chugai Pharmaceutical Co Ltd
US8062638B1 (en) 1999-10-01 2011-11-22 Chugai Seiyaku Kabushiki Kaisha Prevention and treatment of diseases associated with blood coagulation
WO2002064159A1 (fr) 2001-02-07 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Remedes contre les tumeurs affectant les organes hematopoietiques
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
NZ534542A (en) 2002-02-14 2006-08-31 Chugai Pharmaceutical Co Ltd Antibody-containing solutions in which the formation of degradation products and insoluble particles during storage and freeze/thaw cycles is inhibited by adding a sugar and surfactant respectively
JP4489591B2 (ja) 2002-08-27 2010-06-23 中外製薬株式会社 タンパク質溶液製剤の安定化方法
EP2261230B1 (en) 2002-09-11 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Protein purification method
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JPWO2005017155A1 (ja) 2003-06-18 2006-10-12 中外製薬株式会社 フコーストランスポーター
EP2311468B1 (en) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
ATE512232T1 (de) 2003-12-03 2011-06-15 Chugai Pharmaceutical Co Ltd Expressionssystem mit einem säuger-beta-actin- promotor
EP1710255A4 (en) 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
EP1674111B1 (en) 2004-07-09 2010-11-03 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
EP1829961A4 (en) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
BRPI0617378B8 (pt) 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
US8128934B2 (en) 2005-11-14 2012-03-06 Ribomic, Inc. Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
US20100080794A1 (en) 2006-04-14 2010-04-01 Takashi Tsuji Mutant polypeptide having effector function
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
WO2007145227A1 (ja) 2006-06-14 2007-12-21 Chugai Seiyaku Kabushiki Kaisha 造血幹細胞増加促進剤
CN101517075A (zh) 2006-07-13 2009-08-26 中外制药株式会社 细胞死亡诱导剂
JP5175729B2 (ja) 2006-07-21 2013-04-03 中外製薬株式会社 腎疾患治療剤
DE602006013809D1 (de) 2006-07-24 2010-06-02 Facultad De Medicina Universid Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
WO2008020586A1 (fr) 2006-08-14 2008-02-21 Forerunner Pharma Research Co., Ltd. diagnostic et traitement du cancer à l'aide de l'anticorps anti-desmogléine-3
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
KR101493779B1 (ko) 2006-10-12 2015-02-16 츄가이 세이야꾸 가부시키가이샤 항 ｅｒｅｇ 항체를 이용하는 암의 진단 및 치료 방법
JP5378795B2 (ja) 2006-10-20 2013-12-25 中外製薬株式会社 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物
JP5618172B2 (ja) 2007-01-05 2014-11-05 国立大学法人東京大学 抗ｐｒｇ−３抗体を用いる癌の診断および治療
JP5374360B2 (ja) 2007-02-27 2013-12-25 中外製薬株式会社 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物
JP5469456B2 (ja) 2007-06-25 2014-04-16 中外製薬株式会社 ＡＤＣＣ活性又はＣＤＣ活性を有する抗Ｐｒｏｍｉｎｉｎ−１抗体
JP5424330B2 (ja) 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
WO2009044774A1 (ja) 2007-10-02 2009-04-09 Chugai Seiyaku Kabushiki Kaisha インターロイキン６受容体阻害剤を有効成分とする移植片対宿主病治療剤
WO2009054435A1 (ja) 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. 増強されたエフェクター機能を有するポリペプチド
JP5676107B2 (ja) 2007-11-14 2015-02-25 中外製薬株式会社 抗ｇｐｒ４９抗体を用いる癌の診断および治療
AR069333A1 (es) 2007-11-15 2010-01-13 Chugai Pharmaceutical Co Ltd Anticuerpos monoclonales que se unen al receptor tirosin quinasa anexelekto (axl), hibridomas que los producen y sus usos
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
KR20160074019A (ko) 2007-12-05 2016-06-27 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JPWO2009075344A1 (ja) 2007-12-12 2011-04-28 独立行政法人国立がん研究センター Ｍ−ｃｓｆ受容体を分子標的とするｍｌｌ白血病及びｍｏｚ白血病治療剤、およびその利用
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2711557A1 (en) 2008-01-11 2009-07-16 The University Of Tokyo Anti-cldn6 antibody
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
EP2116261A1 (en) 2008-05-07 2009-11-11 Institut Pasteur Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
EP2283862B1 (en) 2008-06-02 2018-08-08 The University of Tokyo Combination treatment of cancer comprising anti-mfg-e8 antibody
CA2728243C (en) 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
CA2728473A1 (en) 2008-06-20 2009-12-23 National University Corporation Okayama University Antibody against oxidized ldl/.beta.2gpi complex and use of the same
WO2010074192A1 (ja) 2008-12-26 2010-07-01 国立大学法人東京大学 抗lgr7抗体を用いる癌の診断および治療
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CA2760642A1 (en) 2009-05-01 2010-11-04 The University Of Tokyo Anti-cadherin antibody
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
MY161541A (en) 2009-07-31 2017-04-28 Shin Maeda Cancer metastasis inhibitor
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
EP2535358B1 (en) 2010-02-10 2017-12-20 Fujifilm RI Pharma Co., Ltd. Radioactive metal-labeled anti-cadherin antibody
JPWO2011105573A1 (ja) 2010-02-26 2013-06-20 株式会社 未来創薬研究所 抗ｉｃａｍ３抗体およびその用途
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
ES2932398T3 (es) 2010-05-28 2023-01-18 Chugai Pharmaceutical Co Ltd Potenciador de la respuesta de las células T antitumorales
EP2632481A1 (en) 2010-10-25 2013-09-04 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
PT2634194T (pt) 2010-10-29 2018-10-19 Perseus Proteomics Inc Anticorpos anti-cdh3 possuidores de elevada capacidade de internalização
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
JP6371059B2 (ja) 2011-10-31 2018-08-08 中外製薬株式会社 重鎖と軽鎖の会合が制御された抗原結合分子
EP2848686B1 (en) 2012-04-04 2024-12-25 Perseus Proteomics Inc. Conjugate of anti-cdh3 (p-cadherin) antibody and drug
WO2014007402A1 (ja) 2012-07-06 2014-01-09 京都府公立大学法人 眼細胞の分化マーカーおよび分化制御
US10689705B2 (en) 2012-09-27 2020-06-23 Chugai Seiyaku Kabushiki Kaisha FGFR3 fusion gene and pharmaceutical drug targeting same
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
JP7050333B2 (ja) 2017-03-24 2022-04-08 全薬工業株式会社 抗ＩｇＭ／Ｂ細胞表面抗原二重特異性抗体
KR102771895B1 (ko) 2017-10-20 2025-02-21 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
US20210363238A1 (en) 2018-01-31 2021-11-25 Motokazu Kato Therapeutic agent for asthma containing il-6 inhibitor
CN113508140B (zh) 2019-02-28 2024-11-19 学校法人顺天堂 与切断型的突变型Calreticulin结合的抗体以及骨髄增殖性肿瘤的诊断、预防或治疗药
KR20220019670A (ko) 2019-04-17 2022-02-17 고쿠리츠다이가쿠호진 히로시마다이가쿠 Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
US20220227887A1 (en) 2019-06-11 2022-07-21 Ono Pharmaceutical Co., Ltd. Immunosuppressant
US20230149555A1 (en) 2020-04-06 2023-05-18 PhotoQ3 Inc. Medicament for killing tumor cells
TW202220694A (zh) 2020-07-28 2022-06-01 日商中外製藥股份有限公司 含有新穎之改變型抗體、具有針套的帶針頭預填充注射器製劑
IL300764A (en) 2020-08-27 2023-04-01 Juntendo Educational Found Antibody and composition of calr-cd3 mutant anti-clotting drugs
US20240158518A1 (en) 2021-03-12 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treatment or prevention of myasthenia gravis
WO2023057871A1 (en) 2021-10-04 2023-04-13 Novartis Ag Surfactant stabilizers
JP7367262B1 (ja) 2021-12-01 2023-10-23 中外製薬株式会社 抗体含有製剤の調製方法
WO2023163087A1 (ja) 2022-02-25 2023-08-31 学校法人順天堂 抗変異ｃａｌｒ抗体と他の薬剤とを組み合わせてなる医薬
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001461A1 (en) * 1980-07-18 1982-05-13 Leland Stanford Junior Univ Human hybridomas,precursors and products
NZ198851A (en) * 1980-11-07 1984-07-31 Wistar Inst Stable,continuous human myeloma cell line capable of hybridisation with antibody-producing cells:production of hybrid cell line

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU589351B2 (en) * 1984-01-31 1989-10-12 Litton Bionetics, Inc. Tumor specific monoclonal antibodies

Also Published As

Publication number Publication date
EP0109441A1 (en) 1984-05-30
HU190908B (en) 1986-12-28
FI86077C (fi) 1992-07-10
FI840219A0 (fi) 1984-01-19
CZ356683A3 (en) 1995-11-15
EP0109441A4 (en) 1986-09-22
DE3382764T2 (de) 1995-03-16
DK25084D0 (da) 1984-01-20
DK25084A (da) 1984-01-20
DK164510C (da) 1992-11-23
JPS58201994A (ja) 1983-11-25
AU1772983A (en) 1983-12-16
WO1983004313A1 (en) 1983-12-08
DE3382764D1 (de) 1994-12-22
IN157982B (enExample) 1986-08-09
ATE114189T1 (de) 1994-12-15
SK279249B6 (sk) 1998-08-05
FI86077B (fi) 1992-03-31
EP0109441B1 (en) 1994-11-17
SK356683A3 (en) 1998-08-05
DK164510B (da) 1992-07-06
FI840219L (fi) 1984-01-19
JPH0159878B2 (enExample) 1989-12-20
ZA833686B (en) 1984-09-26
CZ280677B6 (cs) 1996-04-17
JPS60501359A (ja) 1985-08-22

Similar Documents

Publication Publication Date Title
AU560595B2 (en) Human-human hybridomas for neoplasms
US4618577A (en) Human-human hybridoma, CLNH5
Epstein et al. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors.
US5185432A (en) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
CA1242401A (en) Human monoclonal antibodies to cancer cells
EP1064551A1 (en) Development of human monoclonal antibodies and uses thereof
CA1247538A (en) Human-human hybridomas for solid tumors
EP0232871A2 (en) Human monoclonal antibody, hybridoma producing the same and its use
WO1986007089A1 (en) Murine hybridoma lym-2 and diagnostic antibody produced thereby
US5286647A (en) Human-human hybridomas for neoplasms
JPS59137497A (ja) 抗原特異的免疫グロブリン生産性ヒト／ヒトハイブリド−マ及びその生産する抗体
EP0203552B1 (en) Monoclonal antibodies for human non-small cell lung carcinomas
Dan et al. Human antiglioma monoclonal antibodies from patients with astrocytic tumors
NO165510B (no) Monoklonale antistoffer, samt anvendelse av dem in vitro for bestemmelse av naervaer av neoplasmer.
Hadas et al. Identification of a surface antigen, common to murine lung and Lewis lung carcinoma, by monoclonal antibody
EP0347230A2 (en) Miniclones
Werner et al. Human monoclonal antibodies directed against ovarian carcinoma
Banerjee et al. Human monoclonal antibodies to neuroendocrine granules derived from tumor-infiltrating lymphocytes isolated from a primitive neuroectodermal tumor
JPH01243986A (ja) 抗ヒト固形癌ヒトモノクローナル抗体，抗体産生ハイブリドーマおよび抗体の製造法
EP0285052A2 (en) Monoclonal antibody
JPH0488998A (ja) 腫瘍特異的ヒト型モノクローナル抗体

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired